Cargando…

Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status

BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases...

Descripción completa

Detalles Bibliográficos
Autores principales: S, Mariotto, A, Farinazzo, S, Monaco, A, Gajofatto, G, Zanusso, K, Schanda, R, Capra, C, Mancinelli, A, Bonora, R, Bombardi, M, Reindl, S, Ferrari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703099/
https://www.ncbi.nlm.nih.gov/pubmed/29204292
http://dx.doi.org/10.1177/2055217317743098
_version_ 1783281640610463744
author S, Mariotto
A, Farinazzo
S, Monaco
A, Gajofatto
G, Zanusso
K, Schanda
R, Capra
C, Mancinelli
A, Bonora
R, Bombardi
M, Reindl
S, Ferrari
author_facet S, Mariotto
A, Farinazzo
S, Monaco
A, Gajofatto
G, Zanusso
K, Schanda
R, Capra
C, Mancinelli
A, Bonora
R, Bombardi
M, Reindl
S, Ferrari
author_sort S, Mariotto
collection PubMed
description BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. METHODS: We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. RESULTS: Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis patients (12 pg/ml) and 14 healthy controls (12 pg/ml). CONCLUSIONS: Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an ongoing axonal damage and a more malignant disease course.
format Online
Article
Text
id pubmed-5703099
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-57030992017-12-04 Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status S, Mariotto A, Farinazzo S, Monaco A, Gajofatto G, Zanusso K, Schanda R, Capra C, Mancinelli A, Bonora R, Bombardi M, Reindl S, Ferrari Mult Scler J Exp Transl Clin Short Report BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. METHODS: We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. RESULTS: Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis patients (12 pg/ml) and 14 healthy controls (12 pg/ml). CONCLUSIONS: Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an ongoing axonal damage and a more malignant disease course. SAGE Publications 2017-11-22 /pmc/articles/PMC5703099/ /pubmed/29204292 http://dx.doi.org/10.1177/2055217317743098 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Report
S, Mariotto
A, Farinazzo
S, Monaco
A, Gajofatto
G, Zanusso
K, Schanda
R, Capra
C, Mancinelli
A, Bonora
R, Bombardi
M, Reindl
S, Ferrari
Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title_full Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title_fullStr Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title_full_unstemmed Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title_short Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
title_sort serum neurofilament light chain in nmosd and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703099/
https://www.ncbi.nlm.nih.gov/pubmed/29204292
http://dx.doi.org/10.1177/2055217317743098
work_keys_str_mv AT smariotto serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT afarinazzo serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT smonaco serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT agajofatto serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT gzanusso serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT kschanda serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT rcapra serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT cmancinelli serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT abonora serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT rbombardi serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT mreindl serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus
AT sferrari serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus